Dopamine D3 receptor antagonism contributes to blonanserin-induced cortical dopamine and acetylcholine efflux and cognitive improvement

Pharmacology Biochemistry and Behavior

Volumn 138, Issue , 2015, Pages 49-57

  Huang, Mei ^a   Kwon, Sunoh ^a   Oyamada, Yoshihiro ^a,b   Rajagopal, Lakshmi ^a   Miyauchi, Masanori ^a,b   Meltzer, Herbert Y ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Blonanserin; Cognition; Dopamine D3 receptor; Microdialysis

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; 5 HYDROXYINDOLEACETIC ACID; ACETYLCHOLINE; BLONANSERIN; DOPAMINE; DOPAMINE 3 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NGB 2904; NORADRENALIN; UNCLASSIFIED DRUG; 3,4,4A,10B-TETRAHYDRO-4-PROPYL-2H,5H-(1)BENZOPYRANO(4,3-B)-1,4-OXAZIN-9-OL; AMINO ACID RECEPTOR BLOCKING AGENT; BENZOPYRAN DERIVATIVE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; FLUORENE DERIVATIVE; NOOTROPIC AGENT; OXAZINE DERIVATIVE; PHENCYCLIDINE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE;

5 HYDROXYINDOLEACETIC ACID BRAIN LEVEL; ACETYLCHOLINE BRAIN LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RECEPTOR BLOCKING; DORSAL STRIATUM; DRUG ANTAGONISM; FEMALE; MALE; MEDIAL PREFRONTAL CORTEX; NONHUMAN; NORADRENALIN BRAIN LEVEL; NOVEL OBJECT RECOGNITION TEST; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BRAIN CHEMISTRY; BRAIN CORTEX; C57BL MOUSE; DRUG EFFECTS; LONG EVANS RAT; METABOLISM; MOUSE;

ACETYLCHOLINE; ANIMALS; BENZOPYRANS; BRAIN CHEMISTRY; CEREBRAL CORTEX; DOPAMINE; DOPAMINE ANTAGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FLUORENES; HALOPERIDOL; MALE; MICE; MICE, INBRED C57BL; NOOTROPIC AGENTS; OXAZINES; PHENCYCLIDINE; PIPERAZINES; PIPERIDINES; RATS, LONG-EVANS; RECEPTORS, DOPAMINE D3;

EID: 84941948330     PISSN: 00913057     EISSN: 18735177     Source Type: Journal    
DOI: 10.1016/j.pbb.2015.09.011     Document Type: Article

References (73)

1. E. Aarts, M. van Holstein, and R. Cools Striatal dopamine and the interface between motivation and cognition Front. Psychol. 2 2011 163
2. A.I. Abbas, P.B. Hedlund, X.P. Huang, T.B. Tran, H.Y. Meltzer, and B.L. Roth Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo Psychopharmacology (Berl) 205 1 2009 119 128
3. Y.M. Ahn, K.Y. Lee, C.E. Kim, J.J. Kim, D.Y. Kang, T.Y. Jun, J.S. Choi, I.W. Chung, S.H. Kim, S.S. Hwang, and Y.S. Kim Changes in neurocognitive function in patients with schizophrenia after starting or switching to Amisulpride in comparison with the normal controls J. Clin. Psychopharmacol. 29 2 2009 117 123
4. M. Amargós-Bosch, A. Bortolozzi, M.V. Puig, J. Serrats, A. Adell, P. Celada, M. Toth, G. Mengod, and F. Artigas Co-expression and in vivo interaction of serotonin1A and serotonin2A receptors in pyramidal neurons of prefrontal cortex Cereb. Cortex 14 3 2004 281 299
5. M. Amore, M.C. Jori, and AMISERT investigators Faster response on Amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study Int. Clin. Psychopharmacol. 16 6 2001 317 324
6. E.G. Antzoulatos, and E.K. Miller Differences between neural activity in prefrontal cortex and striatum during learning of novel abstract categories Neuron 71 2011 243 249
7. M.B. Assié, O. Mnie-Filali, V. Ravailhe, C. Benas, M. Marien, C. Bétry, L. Zimmer, N. Haddjeri, and A. Newman-Tancredi F15063, a potential antipsychotic with dopamine D2/D3 receptor antagonist, 5-HT1A receptor agonist and dopamine D4 receptor partial agonist properties: influence on neuronal firing and neurotransmitter release Eur. J. Pharmacol. 607 1-3 2009 74 83
8. S. Baba, T. Enomoto, T. Horisawa, T. Hashimoto, and M. Ono Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range J. Pharmacol. Sci. 127 3 2015 326 331
9. V. Barth, A.B. Need, E.T. Tzavara, B. Giros, C. Overshiner, S.D. Gleason, M. Wade, A.M. Johansson, K. Perry, G.G. Nomikos, and J.M. Witkin In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder J. Pharmacol. Exp. Ther. 344 2 2013 501 510
10. S. Bonaccorso, H.Y. Meltzer, Z. Li, J. Dai, A.R. Alboszta, and J. Ichikawa SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens Neuropsychopharmacology 27 2002 430 441
11. A. Bortolozzi, M. Masana, L. Diaz-Mataix, R. Cortes, M.C. Scorza, J.A. Gingrich, M. Toth, and F. Artigas Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors Int. J. Neuropsychopharmacol. 13 2010 1299 1314
12. M.C. Chen, L. Ferrari, M.D. Sacchet, L.C. Foland-Ross, M.H. Qiu, I.H. Gotlib, P.M. Fuller, E. Arrigoni, and J. Lu Identification of a direct GABAergic pallidocortical pathway in rodents Eur. J. Neurosci. 41 2015 748 759
13. B.D. Devan, N.S. Hong, and R.J. McDonald Parallel associative processing in the dorsal striatum: segregation of stimulus-response and cognitive control subregions Neurobiol. Learn. Mem. 96 2011 95 120
14. A. Ennaceur One-trial object recognition in rats and mice: methodological and theoretical issues Behav. Brain Res. 215 2010 244 254
15. G.L. Gessa, P. Devoto, M. Diana, G. Flore, M. Melis, and M. Pistis Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex Neuropsychopharmacology 22 6 2000 642 649
16. A. Gobert, F. Lejeune, J.M. Rivet, L. Cistarelli, and M.J. Millan Dopamine D3 (auto) receptors inhibit dopamine release in the frontal cortex of freely moving rats in vivo J. Neurochem. 66 5 1996 2209 2212
17. G. Gross, and K. Drescher The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions Handb. Exp. Pharmacol. 167-210 2012
18. G. Gross, K. Wicke, and K.U. Drescher Dopamine D(3) receptor antagonism-still a therapeutic option for the treatment of schizophrenia Naunyn Schmiedeberg's Arch. Pharmacol. 386 2013 155 166
19. A.E. Hackling, and H. Stark Dopamine D3 receptor ligands with antagonist properties Chembiochem 3 2002 946 961
20. H. Hida, A. Mouri, K. Mori, Y. Matsumoto, T. Seki, M. Taniguchi, K. Yamada, K. Iwamoto, N. Ozaki, T. Nabeshima, and Y. Noda Blonanserin ameliorates phencyclidine-induced visual-recognition memory deficits: the complex mechanism of blonanserin action involving D3-5-HTa and D-NMDA receptors in the mPFC Neuropsychopharmacology 40 3 2015 601 613
21. H. Hori, K. Yamada, D. Kamada, Y. Shibata, A. Katsuki, R. Yoshimura, and J. Nakamura Effect of blonanserin on cognitive and social function in acute phase Japanese schizophrenia compared with risperidone Neuropsychiatr. Dis. Treat. 10 2014 527 533
22. M. Horiguchi, and H.Y. Meltzer Blonanserin reverses the phencyclidine (PCP)-induced impairment in novel object recognition (NOR) in rats: role of indirect 5-HT(1A) partial agonism Behav. Brain Res. 247 2013 158 164
23. M. Horiguchi, M. Huang, and H.Y. Meltzer The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats J. Pharmacol. Exp. Ther. 338 2011 605 614
24. M. Horiguchi, K.E. Hannaway, A.E. Adelekun, K. Jayathilake, and H.Y. Meltzer Prevention of the phencyclidine-induced impairment in novel object recognition in female rats by co-administration of lurasidone or tandospirone, a 5-HT(1A) partial agonist Neuropsychopharmacology 37 2012 2175 2183
25. M. Huang, J.J. Panos, S. Kwon, Y. Oyamada, L. Rajagopal, and H.Y. Meltzer Comparative effect of lurasidone and blonanserin on cortical glutamate, dopamine, and acetylcholine efflux: role of relative serotonin (5-HT)2A and DA D2 antagonism and 5-HT1A partial agonism J. Neurochem. 128 2014 938 949
26. J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O'Laughlin, and H.Y. Meltzer 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J. Neurochem. 76 5 2001 1521 1531
27. J. Ichikawa, J. Dai, and H.Y. Meltzer 5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex Brain Res. 939 2002 34 42
28. J. Ichikawa, J. Dai, I.A. O'Laughlin, W.L. Fowler, and H.Y. Meltzer Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum Neuropsychopharmacology 26 2002 325 339
29. P. Jokinen, M. Karrasch, A. Bruck, J. Johansson, J. Bergman, and J.O. Rinne Cognitive slowing in Parkinson's disease is related to frontostriatal dopaminergic dysfunction J. Neurol. Sci. 329 2013 23 28
30. T. Kuroki, H.Y. Meltzer, and J. Ichikawa Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens J. Pharmacol. Exp. Ther. 288 1999 774 781
31. L.P. Lacroix, L. Ceolin, A. Zocchi, G. Varnier, M. Garzotti, O. Curcuruto, and C.A. Heidbreder Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases J. Neurosci. Methods 157 1 2006 25 31
32. B. Landwehrmeyer, G. Mengod, and J.M. Palacios Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography Eur. J. Neurosci. 5 1993 145 153
33. G.M. Leggio, V. Micale, B. Le Foll, C. Mazzola, J.N. Nobrega, and F. Drago Dopamine D3 receptor knock-out mice exhibit increased behavioral sensitivity to the anxiolytic drug diazepam Eur. Neuropsychopharmacol. 21 4 2011 325 332
34. J.F. Liégeois, J. Ichikawa, and H.Y. Meltzer 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner Brain Res. 947 2 2002 157 165
35. F. Loiseau, and M.J. Millan Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists Eur. Neuropsychopharmacol. 19 2009 23 33
36. P.A. MacDonald, A.A. MacDonald, K.N. Seergobin, R. Tamjeedi, H. Ganjavi, J.S. Provost, and O. Monchi The effect of dopamine therapy on ventral and dorsal striatum-mediated cognition in Parkinson's disease: support from functional MRI Brain 134 2011 1447 1463
37. H.Y. Meltzer Attention must be paid: the association of plasma clozapine/NDMC ratio with working memory Am. J. Psychiatry 172 6 2015 502 504
38. H.Y. Meltzer, and M. Huang In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems Prog. Brain Res. 172 2008 177 197
39. H.Y. Meltzer, L. Rajagopal, M. Huang, Y. Oyamada, S. Kwon, and M. Horiguchi Translating the N-methyl-d-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia Int. J. Neuropsychopharmacol. 16 2013 2181 2194
40. V. Micale, L. Cristino, A. Tamburella, S. Petrosino, G.M. Leggio, V. Di Marzo, and F. Drago Enhanced cognitive performance of dopamine D3 receptor "knock-out" mice in the step-through passive-avoidance test: assessing the role of the endocannabinoid/endovanilloid systems Pharmacol. Res. 61 2010 531 536
41. F. Micheli, and C. Heidbreder Selective dopamine D3 receptor antagonists: a review 2001-2005 Recent Pat. CNS Drug Discov. 1 2006 271 288
42. M.J. Millan, A. Gobert, A. Newman-Tancredi, F. Lejeune, D. Cussac, J.M. Rivet, V. Audinot, T. Dubuffet, and G. Lavielle S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626 J. Pharmacol. Exp. Ther. 293 2000 1048 1062
43. M.J. Millan, F. Loiseau, A. Dekeyne, A. Gobert, G. Flik, T.I. Cremers, J.M. Rivet, D. Sicard, R. Billiras, and M. Brocco S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3 H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects J. Pharmacol. Exp. Ther. 324 3 2008 1212 1226
44. M.J. Millan, J.J. Buccafusco, F. Loiseau, D.J. Watson, E. Decamp, K.C. Fone, N. Thomasson-Perret, M. Hill, E. Mocaer, and J.S. Schneider The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures Int. J. Neuropsychopharmacol. 13 2010 1035 1051
45. R. Moraga-Amaro, H. Gonzalez, R. Pacheco, and J. Stehberg Dopamine receptor D3 deficiency results in chronic depression and anxiety Behav. Brain Res. 274 2014 186 193
46. A.M. Mortimer, E. Joyce, K. Balasubramaniam, P.C. Choudhary, P.T. Saleem, and SOLIANOL Study Group Treatment with Amisulpride and olanzapine improve neuropsychological function in schizophrenia Hum. Psychopharmacol. 22 7 2007 445 454
47. S. Nakajima, P. Gerretsen, H. Takeuchi, F. Caravaggio, T. Chow, B. Le Foll, B. Mulsant, B. Pollock, and A. Graff-Guerrero The potential role of dopamine D(3) receptor neurotransmission in cognition Eur. Neuropsychopharmacol. 23 2013 799 813
48. J.C. Neill, M.K. Harte, P.M. Haddad, E.S. Lydall, and D.M. Dwyer Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans Eur. Neuropsychopharmacol. 24 5 2014 822 835
49. K. Ohoyama, S. Yamamura, T. Hamaguchi, M. Nakagawa, E. Motomura, T. Shiroyama, H. Tanii, and M. Okada Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex Eur. J. Pharmacol. 653 1-3 2011 47 57
50. G. Paxinos, and K.B. Franklin The mouse brain in stereotaxic coordinates 2004 Gulf Professional Publishing
51. G. Perrault, R. Depoortere, E. Morel, D.J. Sanger, and B. Scatton Psychopharmacological profile of Amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity J. Pharmacol. Exp. Ther. 280 1997 73 82
52. L.M. Pritchard, A.H. Newman, R.K. McNamara, A.D. Logue, B. Taylor, J.A. Welge, M. Xu, J. Zhang, and N.M. Richtand The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion Pharmacol. Biochem. Behav. 86 2007 718 726
53. T.A. Pugsley, M.D. Davis, H.C. Akunne, R.G. MacKenzie, Y.H. Shih, G. Damsma, H. Wikstrom, S.Z. Whetzel, L.M. Georgic, L.W. Cooke, and et al. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907 J. Pharmacol. Exp. Ther. 275 3 1995 1355 1366
54. L. Rajagopal, B.W. Massey, M. Huang, Y. Oyamada, and H.Y. Meltzer The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia Curr. Pharm. Des. 20 2014 5104 5114
55. K.S. Rayevsky, R.R. Gainetdinov, T.V. Grekhova, and T.D. Sotnikova Regulation of dopamine release and metabolism in rat striatum in vivo: effects of dopamine receptor antagonists Prog. Neuro-Psychopharmacol. Biol. Psychiatry 19 1995 1285 1303
56. L. Redden, B. Rendenbach-Mueller, W.M. Abi-Saab, D.A. Katz, A. Goenjian, W.Z. Robieson, Y. Wang, S.L. Goss, N. Greco IV, and M.D. Saltarelli A double-blind, randomized, placebo-controlled study of the dopamine D receptor antagonist ABT-925 in patients with acute schizophrenia J. Clin. Psychopharmacol. 31 2 2011 221 225
57. H.L. Rowley, P.L. Needham, I.C. Kilpatrick, and D.J. Heal A comparison of the acute effects of zotepine and other antipsychotics on rat cortical dopamine release, in vivo Naunyn Schmiedeberg's Arch. Pharmacol. 361 2 2000 187 192
58. M. Sato, Y. Ago, K. Koda, S. Nakamura, T. Kawasaki, A. Baba, and T. Matsuda Role of postsynaptic serotonin1A receptors in risperidone-induced increase in acetylcholinerelease in rat prefrontal cortex Eur. J. Pharmacol. 559 2-3 2007 155 160
59. A.J. Saykin, R.C. Gur, R.E. Gur, P.D. Mozley, L.H. Mozley, S.M. Resnick, D.B. Kester, and P. Stafiniak Neuropsychological function in schizophrenia. Selective impairment in memory and learning Arch. Gen. Psychiatry 48 1991 618 624
60. J.C. Schwartz, J. Diaz, C. Pilon, and P. Sokoloff Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actions Brain Res. Brain Res. Rev. 31 2000 277 287
61. E.H. Simpson, V. Winiger, D.K. Biezonski, I. Haq, E.R. Kandel, and C. Kellendonk Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition Biol. Psychiatry 76 2014 823 831
62. S. Snigdha, M. Horiguchi, M. Huang, Z. Li, M. Shahid, J.C. Neill, and H.Y. Meltzer Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist J. Pharmacol. Exp. Ther. 332 2010 622 631
63. K. Svensson, A. Carlsson, and N. Waters Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release J. Neural Transm. Gen. Sect. 95 1 1994 71 74
64. Y. Tadori, R.A. Forbes, R.D. McQuade, and T. Kikuchi Functional potencies of dopamine agonists and antagonists at human dopamine D(2) and D(3) receptors Eur. J. Pharmacol. 666 2011 43 52
65. M. Takaki, and H. Ujike Blonanserin, an antipsychotic and dopamine D(2)/D(3)receptor antagonist, and ameliorated alcohol dependence Clin. Neuropharmacol. 36 2013 68 69
66. T. Une, and S. Kurumiya Pharmacological profile of blonanserin Jpn J. Clin. Psychopharmacol. 10 2007 1263 1272
67. M. Wagner, B.B. Quednow, J. Westheide, T.E. Schlaepfer, W. Maier, and K.U. Kuhn Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs Amisulpride Neuropsychopharmacology 30 2005 381 390
68. D.J. Watson, F. Loiseau, M. Ingallinesi, M.J. Millan, C.A. Marsden, and K.C. Fone Selective blockade of dopamine D3 receptors enhances while D2 receptor antagonism impairs social novelty discrimination and novel object recognition in rats: a key role for the prefrontal cortex Neuropsychopharmacology 37 2012 770 786
69. D.M. Weiner, H.Y. Meltzer, I. Veinbergs, E.M. Donohue, T.A. Spalding, T.T. Smith, N. Mohell, S.C. Harvey, J. Lameh, N. Nash, K.E. Vanover, R. Olsson, K. Jayathilake, M. Lee, A.I. Levey, U. Hacksell, E.S. Burstein, R.E. Davis, and M.R. Brann The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine Psychopharmacology (Berl) 177 1-2 2004 207-1
70. N.D. Woodward, S.E. Purdon, H.Y. Meltzer, and D.H. Zald A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia Int. J. Neuropsychopharmacol. 8 2005 457 472
71. K. Yokota, H. Tatebayashi, T. Matsuo, T. Shoge, H. Motomura, T. Matsuno, A. Fukuda, and N. Tashiro The effects of neuroleptics on the GABA-induced Cl- current in rat dorsal root ganglion neurons: differences between some neuroleptics Br. J. Pharmacol. 135 6 2002 1547 1555
72. A. Zapata, J.M. Witkin, and T.S. Shippenberg Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses Neuropharmacology 41 2001 351 359
73. W. Zhang, K.W. Perry, D.T. Wong, B.D. Potts, J. Bao, G.D. Tollefson, and F.P. Bymaster Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex Neuropsychopharmacology 23 3 2000 250 262